Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol
The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
Background Blood pressure reduction achieved with beta-blockers and diuretics is the best recorded intervention to date for prevention of cardiovascular morbidity and death in patients with hypertension. Left ventricular hypertrophy (LVH) is a strong independent indicator of risk of cardiovascular morbidity and death. We aimed to establish whether selective blocking of angiotensin II improves LVH beyond reducing blood pressure and, consequently, reduces cardiovascular morbidity and death. Methods We did a double-masked, randomised, parallel-group trial in 9193 participants aged 55-80 years with essential hypertension (sitting blood pressure 160-200/95-115 mm Hg) and LVH ascertained by electrocardiography (ECG). We assigned participants once daily losartan-based or atenolol-based antihypertensive treatment for at least 4 years and until 1040 patients had a primary cardiovascular event (death, myocardial infarction, or stroke). We used Cox regression analysis to compare regimens. Findings Blood pressure fell by 30.2/16.6 (SD 18.5/10.1) and 29.1/16.8 mm Hg (19.2/10.1) in the losartan and atenolol groups, respectively. The primary composite endpoint occurred in 508 losartan (23.8 per 1000 patient-years) and 588 atenolol patients (27.9 per 1000 patient-years; relative risk 0.87, 95% CI 0.77-0.98, p=0.021). 204 losartan and 234 atenolol patients died from cardiovascular disease (0.89, 0.73-1.07, p=0.206); 232 and 309, respectively, had fatal or non-fatal stroke (0.75, 0.63-0.89, p=…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“an 11% reduction in myocardial infarction (MI)”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [186]
In the citing paper
“This study showed that each 10 mm Hg decrease in systolic BP (achieved with either an ACE inhibitor [captopril] or a beta blocker [atenolol]) was associated with a 15% reduction in DM-related mortality”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [186]
In the citing paper
“and a 13% reduction in the microvascular complications of retinopathy or DKD.186”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [186]
In the citing paper
“Clinical trial data show that intensifying therapy with BP-lowering medications slows the progression of DKD and retinopathy, though vigilance in monitoring renal function during intensive BP therapy is recommended.185,186,201–203”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [186]
In the citing paper
“Optimization of glucose and BP are the proven strategies for primary prevention of diabetic retinopathy and for slowing the progression of preexisting nonproliferative retinopathy.78,185,186,193,522,523”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [186]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
(2000) · New England Journal of Medicine · doi:10.1056/nejm200001203420301 · Cited by 8,663
Brenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H.-H., Remuzzi, G., Snapinn, S. M., Zhang, Z., & Shahinfar, S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011161 · Cited by 7,493
Hansson, L., Lindholm, L. H., Niskanen, L., Lanke, J., Hedner, T., Niklason, A., Luomanmäki, K., Dahlöf, B., de Faire, U., Mörlin, C., et al. (1999) · The Lancet · doi:10.1016/s0140-6736(98)05012-0 · Cited by 2,014
Self-citationMorbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension)
Dahlöf, B., Hansson, L., Lindholm, L. H., Scherstén, B., Ekbom, T., & Wester, P.-O. (1991) · The Lancet · doi:10.1016/0140-6736(91)92589-t · Cited by 1,881
Self-citationAn updated coronary risk profile. A statement for health professionals.
Anderson, K. M., Wilson, P. W., Odell, P. M., & Kannel, W. B. (1991) · Circulation · doi:10.1161/01.cir.83.1.356 · Cited by 1,834
The Norwegian Multicenter Study Group (1981) · New England Journal of Medicine · doi:10.1056/nejm198104023041401 · Cited by 1,675
Hansson, L., Lindholm, L. H., Ekbom, T., Dahlöf, B., Lanke, J., Scherstén, B., Wester, P.-O., Hedner, T., & de Faire, U. (1999) · The Lancet · doi:10.1016/s0140-6736(99)10327-1 · Cited by 1,447
Self-citationReversal of Left Ventricular Hypertrophy in Hypertensive Patients
Dahlöf, B., Pennert, K., & Hansson, L. (1992) · American Journal of Hypertension · doi:10.1093/ajh/5.2.95 · Cited by 925
Self-citationLemon, D. (1987) · The Journal of Emergency Medicine · doi:10.1016/0736-4679(87)90192-2 · Cited by 563
Research works printed but not linked: 2
- Dhlöf, 1997, The Losartan Intervention For Endpoint reduction (LIFE) in Hypertension Study: rationale, design, and methods, Am J Hypertens, 10, 705
- Mulrow, 2001, Pharmacotherapy for hypertension in the elderly (Cochrane review)
Cited by
Items 601–700 of 1,018
Mcinnes, G. T. (2003) · The British Journal of Diabetes & Vascular Disease · doi:10.1177/14746514030030040501 · Cited by 117
Williams, B. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2004.10.069 · Cited by 117
Julius, S. (2003) · American Journal of Hypertension · doi:10.1016/s0895-7061(03)00904-x · Cited by 117
Self-citationDiabetic Nephropathy: The Proteinuria Hypothesis
Williams, M. E. (2005) · American Journal of Nephrology · doi:10.1159/000084286 · Cited by 117
Value of Noninvasive Hemodynamics to Achieve Blood Pressure Control in Hypertensive Subjects
Smith, R. D., Levy, P. J., & Ferrario, C. M. (2006) · Hypertension · doi:10.1161/01.hyp.0000209642.11448.e0 · Cited by 116
Bottom blood pressure or bottom cardiovascular risk? How far can cardiovascular risk be reduced?
Zanchetti, A. (2009) · Journal of Hypertension · doi:10.1097/hjh.0b013e32832e9500 · Cited by 116
Diabetes, prediabetes, and cardiovascular risk: Shifting the paradigm
DEEDWANIA, P. C., & Fonseca, V. A. (2005) · The American Journal of Medicine · doi:10.1016/j.amjmed.2005.05.018 · Cited by 116
Matsuzaki, M., Ogihara, T., Umemoto, S., Rakugi, H., Matsuoka, H., Shimada, K., Abe, K., Suzuki, N., Eto, T., Higaki, J., et al. (2011) · Journal of Hypertension · doi:10.1097/hjh.0b013e328348345d · Cited by 116
Garg, J. P., Chasan-Taber, S., Blair, A. T., Plone, M. A., Bommer, J., Raggi, P., & Chertow, G. M. (2005) · Arthritis & Rheumatism · doi:10.1002/art.20781 · Cited by 116
Miura, Y., Yamamoto, N., Tsunekawa, S., Taguchi, S., Eguchi, Y., Ozaki, N., & Oiso, Y. (2005) · Diabetes Care · doi:10.2337/diacare.28.3.757 · Cited by 116
Angiotensin Receptor Blockers: Pharmacology, Efficacy, and Safety
Taylor, A. A., Siragy, H. M., & Nesbitt, S. D. (2011) · Journal of Clinical Hypertension · doi:10.1111/j.1751-7176.2011.00518.x · Cited by 115
Szwejkowski, B. R., Gandy, S. J., Rekhraj, S., Houston, J. G., Lang, C. C., Morris, A. D., George, J., & Struthers, A. D. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.07.074 · Cited by 115
Nebivolol Increases Arterial Distensibility In Vivo
McEniery, C. M., Schmitt, M., Qasem, A., Webb, D. J., Avolio, A. P., Wilkinson, I. B., & Cockcroft, J. R. (2004) · Hypertension · doi:10.1161/01.hyp.0000137983.45556.6e · Cited by 115
Williams, B. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.08.037 · Cited by 115
Tai, D. J., Lim, T. W., James, M. T., Manns, B., Tonelli, M. A., & Hemmelgarn, B. R. (2010) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.07831109 · Cited by 115
RAS inhibition in hypertension
Ibrahim, M. M. (2006) · Journal of Human Hypertension · doi:10.1038/sj.jhh.1001960 · Cited by 114
Inaba, S., Iwai, M., Furuno, M., Tomono, Y., Kanno, H., Senba, I., Okayama, H., Mogi, M., Higaki, J., & Horiuchi, M. (2009) · Hypertension · doi:10.1161/hypertensionaha.108.123612 · Cited by 114
The importance of blood pressure control in the patient with diabetes
Bakris, G. L. (2004) · The American Journal of Medicine · doi:10.1016/j.amjmed.2003.10.018 · Cited by 114
Wada, T., Ohshima, S., Fujisawa, E., Koya, D., Tsuneki, H., & Sasaoka, T. (2009) · Endocrinology · doi:10.1210/en.2008-1018 · Cited by 114
Angiotensin‐(1‐7): Pharmacology and New Perspectives in Cardiovascular Treatments
Trask, A. J., & Ferrario, C. M. (2007) · Cardiovascular Drug Reviews · doi:10.1111/j.1527-3466.2007.00012.x · Cited by 114
2019 Chinese guideline for the management of hypertension in the elderly.
Hua, Q., Fan, L. H., & Li, J. (2019) · PubMed Central · doi:10.11909/j.issn.1671-5411.2019.02.001 · Cited by 113
Treatment of Cardiovascular and Renal Risk Factors in the Diabetic Hypertensive
Sowers, J. R., & Haffner, S. M. (2002) · Hypertension · doi:10.1161/01.hyp.0000042097.39655.b7 · Cited by 113
Harris, R., Donahue, K., Rathore, S. S., Frame, P., Woolf, S. H., & Lohr, K. N. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-138-3-200302040-00015 · Cited by 113
Ni, W., Kitamoto, S., Ishibashi, M., Usui, M., Inoue, S., Hiasa, K., Zhao, Q. D., Nishida, K.-I., Takeshita, A., & Egashira, K. (2004) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000118275.60121.2b · Cited by 113
Casey, D. E., Thomas, R. J., Bhalla, V., Commodore-Mensah, Y. Y., Heidenreich, P. A., Kolte, D. S., Muntner, P., Smith, S. C., Spertus, J. A., Windle, J. R., et al. (2019) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/hcq.0000000000000057 · Cited by 113
Carvedilol in hypertension treatment
Stafylas, P. C., & Sarafidis, P. A. (2008) · Vascular Health and Risk Management · doi:10.2147/vhrm.2008.04.01.23 · Cited by 113
White, H. D., Aylward, P. E., Huang, Z., Dalby, A. J., Weaver, W. D., Barvik, S., Marin‐Neto, J. A., Murín, J., Nordlander, R., van Gilst, W. H., et al. (2005) · Circulation · doi:10.1161/circulationaha.105.551143 · Cited by 113
Mineralocorticoid receptors in immune cells: Emerging role in cardiovascular disease
Bene, N. C., Alcaide, P., Wortis, H. H., & Jaffe, I. Z. (2014) · Steroids · doi:10.1016/j.steroids.2014.04.005 · Cited by 112
Trespalacios, F. C., Taylor, A. J., Agodoa, L. Y. C., & Abbott, K. C. (2002) · Kidney International · doi:10.1046/j.1523-1755.2002.00638.x · Cited by 112
Simpson, R. W., Shaw, J. E., & Zimmet, P. (2003) · Diabetes Research and Clinical Practice · doi:10.1016/s0168-8227(02)00275-9 · Cited by 112
Yasunari, K., Maeda, K., Watanabe, T., Nakamura, M., Yoshikawa, J., & Asada, A. (2004) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2003.12.051 · Cited by 112
Hypertension and acute myocardial infarction: an overview
Pedrinelli, R., Ballo, P., Fiorentini, C., Denti, S., Galderisi, M., Ganau, A., Germanò, G., Innelli, P., Paini, A., Perlini, S., et al. (2012) · Journal of Cardiovascular Medicine · doi:10.2459/jcm.0b013e3283511ee2 · Cited by 112
Yamagishi, S., Nakamura, K., Ueda, S., Kato, S., & Imaizumi, T. (2005) · Cell and Tissue Research · doi:10.1007/s00441-005-1094-8 · Cited by 111
Antihypertensive Medications and the Risk of Incident Type 2 Diabetes
Taylor, E. N. (2006) · Diabetes Care · doi:10.2337/diacare.2951065 · Cited by 111
Prognostic value of electrocardiographic criteria for left ventricular hypertrophy
Hsieh, B. P. C., Pham, M., & Froelicher, V. F. (2005) · American Heart Journal · doi:10.1016/j.ahj.2004.08.041 · Cited by 111
Lessons Learned From Recent Cardiovascular Clinical Trials: Part I
DeMets, D. L., & Califf, R. M. (2002) · Circulation · doi:10.1161/01.cir.0000023219.51483.66 · Cited by 110
Baker, D. W. (2002) · Journal of Cardiac Failure · doi:10.1054/jcaf.2002.0805333 · Cited by 110
Hove, K. D., Brøns, C., Færch, K., Lund, S. S., Rossing, P., & Vaag, A. (2015) · European Journal of Endocrinology · doi:10.1530/eje-14-0554 · Cited by 109
Vascular endothelial ageing, heartbeat after heartbeat
Thorin, É., & Thorin‐Trescases, N. (2009) · Cardiovascular Research · doi:10.1093/cvr/cvp236 · Cited by 109
β-Blockers: A Review of Their Pharmacological and Physiological Diversity in Hypertension
Ripley, T. L., & Saseen, J. J. (2014) · Annals of Pharmacotherapy · doi:10.1177/1060028013519591 · Cited by 109
Concise Review: Rational Use of Mesenchymal Stem Cells in the Treatment of Ischemic Heart Disease
Ward, M. R., Abadeh, A., & Connelly, K. A. (2018) · Stem Cells Translational Medicine · doi:10.1002/sctm.17-0210 · Cited by 109
Bushnell, C., Culebras, A., DeGraba, T. J., Goldstein, B. A., Adams, R. J., Alberts, M. J., & Appel, L. J. (2006) · Cited by 108
Beta-Blockers for Primary Prevention of Heart Failure in Patients With Hypertension
Bangalore, S., Wild, D. M., Parkar, S., Kukin, M. L., & Messerli, F. H. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.05.057 · Cited by 108
Cerebral Ischemia Enhances Vascular Angiotensin AT 1 Receptor–Mediated Contraction in Rats
Stenman, E., & Edvinsson, L. I. (2004) · Stroke · doi:10.1161/01.str.0000121642.53822.58 · Cited by 108
Bang, C. N., Devereux, R. B., & Okin, P. M. (2014) · Journal of Electrocardiology · doi:10.1016/j.jelectrocard.2014.07.003 · Cited by 110
Self-citationAn orally active formulation of angiotensin-(1-7) produces an antithrombotic effect
Fraga-Silva, R. A., Costa-Fraga, F. P., De Sousa, F. B., Alenina, N., Bader, M., Sinisterra, R. D., & Santos, R. A. S. (2011) · Clinics · doi:10.1590/s1807-59322011000500021 · Cited by 108
Kalehoff, J. P., & Oparil, S. (2020) · Current Hypertension Reports · doi:10.1007/s11906-020-01077-7 · Cited by 108
Self-citationNew insights into angiotensin receptor actions: from blood pressure to aging
Stegbauer, J., & Coffman, T. M. (2010) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0b013e3283414d40 · Cited by 108
Omapatrilat—the story of Overture and Octave
Coats, A. J. S. (2002) · International Journal of Cardiology · doi:10.1016/s0167-5273(02)00389-3 · Cited by 107
DEEDWANIA, P. C. (2010) · Journal of Clinical Hypertension · doi:10.1111/j.1751-7176.2010.00386.x · Cited by 107
Aging, Resting Metabolic Rate, and Oxidative Damage: Results From the Louisiana Healthy Aging Study
Frisard, M. I., Broussard, A., Davies, S. S., Roberts, L. J., Rood, J., Jonge, L. D., Fang, X., Jazwinski, S. M., Deutsch, W. A., Ravussin, E., et al. (2007) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/62.7.752 · Cited by 106
Gavin, A. D., & Struthers, A. D. (2005) · Heart · doi:10.1136/hrt.2004.040477 · Cited by 106
Kowaltowski, A. J., & Abdulkader, F. (2020) · Springer eBooks · doi:10.1007/978-3-030-50968-2_9 · Cited by 106
Thomopoulos, C., Parati, G., & Zanchetti, A. (2018) · Journal of Hypertension · doi:10.1097/hjh.0000000000001777 · Cited by 106
Ictus. Diagnóstico y tratamiento de las enfermedades cerebrovasculares
Ustrell, X., & Serena, J. L. (2007) · Revista Española de Cardiología · doi:10.1157/13108281 · Cited by 115
The ACTIVE Steering Committee (2006) · American Heart Journal · doi:10.1016/j.ahj.2005.06.026 · Cited by 105
Combination therapy for dyslipidemia: safety and regulatory considerations
Davidson, M. H. (2002) · The American Journal of Cardiology · doi:10.1016/s0002-9149(02)02970-3 · Cited by 105
Mogi, M., Li, J., Iwanami, J., Min, L., Tsukuda, K., Iwai, M., & Horiuchi, M. (2006) · Hypertension · doi:10.1161/01.hyp.0000229648.67883.f9 · Cited by 105
Gilbert, R. E., Krum, H., Wilkinson‐Berka, J. L., & Kelly, D. J. (2003) · Diabetic Medicine · doi:10.1046/j.1464-5491.2003.00979.x · Cited by 105
Kintscher, U., Bramlage, P., Paar, W. D., Thoenes, M., & Unger, T. (2007) · Cardiovascular Diabetology · doi:10.1186/1475-2840-6-12 · Cited by 105
Wang, J., Li, Y., Franklin, S. S., & Safar, M. E. (2007) · Hypertension · doi:10.1161/hypertensionaha.107.089763 · Cited by 107
Inflammation in Acute Ischemic Stroke and its Relevance to Stroke Critical Care
Emsley, H. C. A., Smith, C. J., Tyrrell, P. J., & Hopkins, S. J. (2007) · Neurocritical Care · doi:10.1007/s12028-007-9035-x · Cited by 105
Mancia, G., Ambrosioni, E., Rosei, E. A., Leonetti, G., Trimarco, B., & Volpe, M. (2005) · Journal of Hypertension · doi:10.1097/01.hjh.0000175932.78774.32 · Cited by 104
Hypertension and the Metabolic Syndrome
Morse, S. A., Zhang, R., Thakur, V., & Reisin, E. (2005) · The American Journal of the Medical Sciences · doi:10.1097/00000441-200512000-00008 · Cited by 104
Mason, J. M., Dickinson, H. O., Nicolson, D. J., Campbell, F., Ford, G. A., & Williams, B. (2005) · Journal of Hypertension · doi:10.1097/01.hjh.0000177537.91527.09 · Cited by 104
Crowley, S. D., Vasievich, M. P., Ruiz, P., Gould, S., Parsons, K. K., Pazmino, A. K., Facemire, C. S., Chen, B. J., Kim, H., Tran, T. T., et al. (2009) · Journal of Clinical Investigation · doi:10.1172/jci34862 · Cited by 105
Manabe, S., Okura, T., Watanabe, S., Fukuoka, T., & Higaki, J. (2005) · Journal of Cardiovascular Pharmacology · doi:10.1097/01.fjc.0000185783.00391.60 · Cited by 103
Vitamin D, the renin-angiotensin system, and insulin resistance
Rammos, G., Tseke, P., & Ziakka, S. (2008) · International Urology and Nephrology · doi:10.1007/s11255-007-9244-4 · Cited by 103
Inflammation and the metabolic syndrome: Role of angiotensin II and oxidative stress
Ferder, L., Inserra, F., & Martínez–Maldonado, M. (2006) · Current Hypertension Reports · doi:10.1007/s11906-006-0050-7 · Cited by 103
Regulation of Peroxisome Proliferator–Activated Receptor γ Activity by Losartan Metabolites
Schupp, M., Lee, L. D., Frost, N., Umbreen, S., Schmidt, B., Unger, T., & Kintscher, U. (2005) · Hypertension · doi:10.1161/01.hyp.0000196946.79674.8b · Cited by 103
Angiotensin II Receptor Blockade: Is There Truly a Benefit of Adding an ACE Inhibitor?
Forclaz, A., Maillard, M. P., Nussberger, J., Brunner, H. R., & Burnier, M. (2003) · Hypertension · doi:10.1161/01.hyp.0000047512.58862.a9 · Cited by 103
Butlin, M., Qasem, A., & Avolio, A. P. (2012) · Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC) · doi:10.1109/embc.2012.6346494 · Cited by 103
Albuminuria, not only a cardiovascular/renal risk marker, but also a target for treatment?
de Zeeuw, D. (2004) · Kidney International · doi:10.1111/j.1523-1755.2004.09201.x · Cited by 102
Sodium Intake Regulates Glucose Homeostasis through the PPARδ/Adiponectin-Mediated SGLT2 Pathway
Zhao, Y., Gao, P., Sun, F., Li, Q., Chen, J., Yu, H., Li, L., Wei, X., He, H., Lu, Z., et al. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.02.019 · Cited by 103
Barriers to cardiovascular disease risk scoring and primary prevention in Europe
Hobbs, F. D. R., Jukema, J. W., Da Silva, P. M., McCormack, T., & Catapano, A. L. (2010) · QJM · doi:10.1093/qjmed/hcq122 · Cited by 102
PROTECT: A coordinated stroke treatment program to prevent recurrent thromboembolic events
Ovbiagele, B. I., Saver, J. L., Fredieu, A., Suzuki, S., McNair, N. D., Dandekar, A., Razinia, T., & Kidwell, C. S. (2004) · Neurology · doi:10.1212/01.wnl.0000140493.83607.f1 · Cited by 102
Blood pressure control and cardiovascular risk reduction.
Antonakoudis, G., Poulimenos, L. E., Kifnidis, K., Zouras, C., & Antonakoudis, H. (2007) · PubMed Central · Cited by 102
Perticone, F., Maio, R., Sciacqua, A., Andreozzi, F., Iemma, G., Perticone, M., Zoccali, C., & Sesti, G. (2007) · Diabetes · doi:10.2337/db07-1189 · Cited by 102
ACE2: A novel therapeutic target for cardiovascular diseases
Sarkissian, S. D., Huentelman, M. J., Stewart, J. M., Katovich, M. J., & Raizada, M. K. (2005) · Progress in Biophysics and Molecular Biology · doi:10.1016/j.pbiomolbio.2005.05.011 · Cited by 102
Williams, B. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.06.074 · Cited by 102
Kizer, J. R., Dahlöf, B., Kjeldsen, S. E., Julius, S., Beevers, G., de Faire, U., Fyhrquist, F., Ibsen, H., Kristianson, K., Lederballe-Pedersen, O., et al. (2005) · Hypertension · doi:10.1161/01.hyp.0000151324.05355.1c · Cited by 101
Self-citationTreatment of Hypertension in Patients With Diabetes
Sowers, J. R. (2004) · Archives of Internal Medicine · doi:10.1001/archinte.164.17.1850 · Cited by 101
González‐Juanatey, J. R., Ramos, P. M., Arcos, F. S., Alonso, V. B., Padial, L. R., & Bertoméu, V. (2003) · Revista Española de Cardiología · doi:10.1016/s0300-8932(03)76904-8 · Cited by 103
Statin and β-Blocker Therapy and the Initial Presentation of Coronary Heart Disease
Go, A. S., Iribarren, C., Chandra, M., Lathon, P. V., Fortmann, S. P., Quertermous, T., Hlatky, M. A., & for the Atherosclerotic Disease, V. F. A. G. E. (. S. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-144-4-200602210-00004 · Cited by 101
Zidek, W., Schrader, J., Lüders, S., Matthaei, S., Hasslacher, C., Hoyer, J. D., Zemmrich, C., Bramlage, P., Sturm, C., & Paar, W. D. (2012) · Cardiovascular Diabetology · doi:10.1186/1475-2840-11-1 · Cited by 100
Progression of Cardiovascular Damage: The Role of Renin–Angiotensin System Blockade
Probstfield, J. L., & O’Brien, K. D. (2009) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2009.10.006 · Cited by 100
Atherosclerosis and Oxidant Stress: The End of the Road for Antioxidant Vitamin Treatment?
Thomson, M. J. C. B., Püntmann, V. O., & Kaski, J. C. (2007) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-007-6027-1 · Cited by 100
Thomopoulos, C., Parati, G., & Zanchetti, A. (2016) · Journal of Hypertension · doi:10.1097/hjh.0000000000001052 · Cited by 100
Guidelines for the Management of Hypertension
Chobanian, A. V. (2016) · Medical Clinics of North America · doi:10.1016/j.mcna.2016.08.016 · Cited by 102
Guías de práctica clínica para el tratamiento de la hipertensión arterial 2007
(ESH), G. D. T. P. E. T. D. L. H. A. D. L. S. E. D. H., & de Cardiología, D. L. S. E. (2007) · Revista Española de Cardiología · doi:10.1157/13109650 · Cited by 100
Antihypertensive drugs and glucose metabolism
Rizos, C. V., & Elisaf, M. (2014) · World Journal of Cardiology · doi:10.4330/wjc.v6.i7.517 · Cited by 99
Management of Dyslipidemia in Patients with Hypertension, Diabetes, and Metabolic Syndrome
Srikanth, S., & DEEDWANIA, P. C. (2016) · Current Hypertension Reports · doi:10.1007/s11906-016-0683-0 · Cited by 99
Impact of Hypertension on Stroke
Dubow, J. S., & Fink, M. E. (2011) · Current Atherosclerosis Reports · doi:10.1007/s11883-011-0187-y · Cited by 99
International Society of Hypertension Writing Group (2003) · Journal of Hypertension · doi:10.1097/00004872-200304000-00002 · Cited by 100
Protective Effects of Angiotensin II Interruption: Evidence for Antiinflammatory Actions
Dagenais, N. J., & Jamali, F. (2005) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.2005.25.9.1213 · Cited by 99
Medical Therapies for Heart Failure With Preserved Ejection Fraction
Kjeldsen, S. E., von Lueder, T. G., Smiseth, O. A., Wachtell, K., Mistry, N., Westheim, A. S., Hopper, I., Julius, S., Pitt, B., Reid, C. M., et al. (2019) · Hypertension · doi:10.1161/hypertensionaha.119.14057 · Cited by 98
Self-citationKatz, D. H., Deo, R. C., Aguilar, F. G., Selvaraj, S., Martinez, E. E., Beussink‐Nelson, L., Kim, K. A., Peng, J., Irvin, M. R., Tiwari, H. K., et al. (2017) · Journal of Cardiovascular Translational Research · doi:10.1007/s12265-017-9739-z · Cited by 99
Thomopoulos, C., Parati, G., & Zanchetti, A. (2016) · Journal of Hypertension · doi:10.1097/hjh.0000000000000848 · Cited by 98
Beta-blockers for hypertension
Wiysonge, C. S., Bradley, H. A., Volmink, J., Mayosi, B. M., Mbewu, A., & Opie, L. H. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002003.pub3 · Cited by 97
Candesartan inhibits Toll-like receptor expression and activity both in vitro and in vivo
Dasu, M. R. K., Riosvelasco, A. C., & Jialal, I. (2008) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2008.04.010 · Cited by 96
Metadata
- Authors
- Dahlöf, B., Devereux, R. B., Kjeldsen, S. E., Julius, S., Beevers, G., de Faire, U., Fyhrquist, F., Ibsen, H., Kristiansson, K., Lederballe-Pedersen, O., Lindholm, L. H., Nieminen, M. S., Omvik, P., Oparil, S., & Wedel, H.
- Affiliations
- Sahlgrenska University Hospital (SE)
- Oslo University Hospital (NO)
- University of Michigan (US)
- Birmingham City Hospital (GB)
- Helsinki University Hospital (FI)
- Glostrup Hospital (DK)
- Umeå University (SE)
- Haukeland University Hospital (NO)
- University of Alabama at Birmingham (US)
- Nordic School of Public Health (SE)
- Corresponding author
- Dahlöf, Björn
- ORCID
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2002-03
- Volume
- 359
- Issue
- 9311
- Pages
- 995-1003
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W2133217116
- Cited by
- 5,407
- References
- 29
- Citations by year
- 2026: 37 · 2025: 51 · 2024: 51 · 2023: 69 · 2022: 63 · 2021: 75 · 2020: 74 · 2019: 82 · 2018: 106 · 2017: 144 · 2016: 131 · 2015: 152 · 2014: 208 · 2013: 200 · 2012: 265
- FWCI
- 333.38
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- Locations
- The Lancet (publishedVersion)
- PubMed (publishedVersion)
- UEA Digital Repository (University of East Anglia) (submittedVersion)
- STM:n Hallinnonalan avoin julkaisuarkisto (Julkari) (submittedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Renin-Angiotensin System Studies
- Health Sciences › Nursing › Nutrition and Dietetics › Sodium Intake and Health
- Keywords
- atenolol, essential hypertension, left ventricular hypertrophy, angiotensin receptor blockers, beta-blockers, cardiovascular morbidity, cardiovascular mortality, stroke, myocardial infarction, blood pressure reduction, new-onset diabetes, antihypertensive therapy, elderly patients, secondary prevention of cardiovascular disease, renin-angiotensin system blockade
- MeSH terms
- Aged, Aged, 80 and over, Antihypertensive Agents, Atenolol, Cardiovascular Diseases, Double-Blind Method, Female, Humans, Hypertension, Male, Middle Aged, Losartan, Diabetes Complications, Angiotensin Receptor Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.